Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V2OL
|
|||
| Former ID |
DNCL003660
|
|||
| Drug Name |
NN1841
|
|||
| Synonyms |
NovoThirteen (TN)
Click to Show/Hide
|
|||
| Indication | Hemophilia [ICD-11: 3B10.0; ICD-10: D66-D68; ICD-9: 286] | Phase 3 | [1] | |
| Company |
Novo Nordisk
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor XIII (F13B) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Common Pathway of Fibrin Clot Formation | |||
| WikiPathways | Human Complement System | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01253811) Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency. U.S.National Institutes of Health. | |||
| REF 2 | Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency. J Blood Med. 2014 Jul 9;5:107-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.